Created with BioGDP.com[1]
Considering that there is little real-world data on the use of anticoagulant monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (SCAD), and the impact of SCAD on anticoagulation monotherapy remains unclear.
We collected data on ABCB1 genotype, drug combinations, and other baseline conditions of NVAF patients with and without SCAD. Then we evaluated the potential effects of SCAD on plasma concentration, coagulation function, and adverse events in NVAF patients receiving rivaroxaban monotherapy through propensity score matching.
Our results indicate that anticoagulation monotherapy was associated with a higher risk of minor bleeding and total bleeding in SCAD patients compared to non-SCAD patients. And more clinical attention should be paid to SCAD patients with an myocardial infarction history, as they are at higher risk for serious bleeding. About coagulation function, prothrombin time–international normalized ratio (PT-INR) was nonlinearly, positively correlated with the risk of total bleeding in SCAD patients.
[1] Jiang S, Li H, Zhang L, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025, 53 (D1), D1670–D1676.
Chen, M.Y. et al. / J. Chin. Pharm. Sci. 2025, 34 (11), 989–1002.
>
>